1399849-64-9

Basic information

• Product Name: 3-Acetyl-6-Methyl-7-azaindole
• Synonyms: 3-Acetyl-6-Methyl-7-azaindole
• CAS NO: 1399849-64-9
• Molecular Formula: C10H10N2O
• Molecular Weight: 174.1992
• Mol File: 1399849-64-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.219±0.06 g/cm3(Predicted)
• PKA: 12.61±0.40(Predicted)
• CAS DataBase Reference: 3-Acetyl-6-Methyl-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Acetyl-6-Methyl-7-azaindole(1399849-64-9)
• EPA Substance Registry System: 3-Acetyl-6-Methyl-7-azaindole(1399849-64-9)

Safety Data

• Hazardous Substances Data: 1399849-64-9(Hazardous Substances Data)

Upstream product

• 75-36-5 acetyl chloride 
• 824-51-1 6-methyl-1H-pyrrolo<2,3-b>pyridine 
• 55052-27-2 6-chloro-7-azaindole 
• 271-63-6 7-Azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 143468-11-5 1-Benzoyl-6-chloro-1H-pyrrolo<2,3-b>pyridine 
• 896722-50-2 1-benzenesulfonyl-6-chloro-1H-pyrrolo[2,3-b]pyridine 
• 896722-51-3 1-benzenesulfonyl-6-methyl-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

Multiple lines of evidence have indicated that pyruvate kinase M2 (PKM2) is upregulated in most cancer cells and it is increasingly recognized as a potential therapeutic target in oncology. In a continuation of our discovery of lead compound 5 and SAR study, the 7-azaindole moiety in compound 5 was systematically optimized. The results showed that compound 6f, which has a difluoroethyl substitution on the 7-azaindole ring, exhibited high PKM2 activation potency and anti-proliferation activities on A375 cell lines. In a xenograft mouse model, oral administration of compound 6f led to significant tumor regression without obvious toxicity. Further mechanistic studies revealed that 6f could influence the translocation of PKM2 into nucleus, as well as induction of apoptosis and autophagy of A375 cells. More importantly, compound 6f significantly inhibited migration of A375 cells in a concentration-dependent manner. Collectively, 6f may serve as a lead compound in the development of potent PKM2 activators for cancer therapy.

NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is -O- and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.